Skip to contentpdufa.bio

bezuclastinib SUMMIT

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

bezuclastinib SUMMIT is a Cogent Biosciences program in nonadvanced systemic mastocytosis (switch from avapritinib). Its next catalyst is a Readout in Dec 2026.

COGT catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: nonadvanced systemic mastocytosis (switch from avapritinib). Sponsor: Cogent Biosciences (COGT). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2026COGT

Specialist biotech funds holding COGT, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RTW Investments2,309,021$73.9 millionfiled November 16, 2026
OrbiMed Advisors2,003,700$64.2 millionfiled November 16, 2026
Redmile Group296,606$9.5 millionfiled November 16, 2026
Cormorant Asset Management30,000$960,600filed November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is bezuclastinib SUMMIT's next FDA decision or readout?

The next tracked catalyst for bezuclastinib SUMMIT is a Readout in Dec 2026.

What happened at bezuclastinib SUMMIT's most recent FDA decision?

No FDA decision for bezuclastinib SUMMIT is in our archive yet.

What is bezuclastinib SUMMIT used for?

In our records bezuclastinib SUMMIT is under review or in development for nonadvanced systemic mastocytosis (switch from avapritinib).

Who makes bezuclastinib SUMMIT?

Cogent Biosciences (COGT).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.